The Sound of Evolution
Fosamprenavir
Mechanism of action:
Fosamprenavir is a protease inhibitor prodrug of amprenavir, an HIV protease inhibitor. Fosamprenavir is hydrolyzed by alkaline phosphatase in the intestine and liver to its active form, amprenavir. Amprenavir selectively binds to the active site of HIV-1 protease and blocks the cleavage of Gag and Gag-Pol polyprotein precursors, resulting in structurally incomplete and noninfectious viral particles.
Reference(s):
1. Smith KY et al. (2008). Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther.
2. Hoffman RM et al. (2007). Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials.
3. Chapman TM et al. (2004). Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs.